Realgar induces apoptosis in the chronic lymphocytic leukemia cell line MEC‑1

Liu,Xinyu; Li,Xianglu; Wang,Ling; Lv,Xiao; Chen,Na; Li,Peipei; Lu,Kang; Wang,Xin

doi:10.3892/mmr.2013.1731

Realgar induces apoptosis in the chronic lymphocytic leukemia cell line MEC‑1

Authors:
- Xinyu Liu
- Xianglu Li
- Ling Wang
- Xiao Lv
- Na Chen
- Peipei Li
- Kang Lu
- Xin Wang
View Affiliations

Affiliations: Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: October 14, 2013 https://doi.org/10.3892/mmr.2013.1731
Pages: 1866-1870

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of realgar on the viability, proliferation and apoptosis in the human chronic lymphocytic leukemia (CLL) cell line, MEC‑1. Potential mechanisms mediating the effect were also explored in the experiment. Cultured MEC‑1 cells were incubated with various concentrations of realgar for 24, 48 and 72 h. A WST‑8 assay was employed to evaluate the effect on cell viability. Inhibitory effects on cell proliferation were determined using a 5‑bromodeoxyuridine cell proliferation ELISA. The apoptotic effect on MEC‑1 cells was evaluated by annexin V‑fluorescein isothiocyanate/propidium iodide dual staining, followed by flow cytometry. Quantitative polymerase chain reaction was performed to determine the mRNA expression levels of BCL2‑associated X protein (BAX), BCL2‑like 1 (Bcl-xL), v‑myc myelocytomatosis viral oncogene homolog (avian; c‑Myc) and cyclin‑dependent kinase inhibitor 1A (p21). It was found that viability and proliferation were significantly reduced while apoptotic rates increased in MEC‑1 cells following exposure to realgar. Furthermore, mRNA expression of BAX and c‑Myc was upregulated and downregulated, respectively, in realgar‑treated MEC‑1 cells. In conclusion, the results showed that realgar inhibits viability and proliferation and induces apoptosis of MEC‑1 cells in a dose‑ and time‑dependent manner. The effect may depend on the mitochondrial apoptosis pathway. The results of the present study may be beneficial in the identification of a new target therapy for CLL.

View Figures

View References

1	Man S, Gao W, Wei C and Liu C: Anticancer drugs from traditional toxic Chinese medicines. Phytother Res. 26:1449–1465. 2012.PubMed/NCBI
2	Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 339:1341–1348. 1998. View Article : Google Scholar : PubMed/NCBI
3	Lu J, Chew EH and Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA. 104:12288–12293. 2007. View Article : Google Scholar : PubMed/NCBI
4	Hu J, Liu YF, Wu CF, et al: Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 106:3342–3347. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kim J, Lee JJ, Kim J, Gardner D and Beachy PA: Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA. 107:13432–13437. 2010. View Article : Google Scholar : PubMed/NCBI
6	Zhang XW, Yan XJ, Zhou ZR, et al: Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 328:240–243. 2010. View Article : Google Scholar : PubMed/NCBI
7	Mahieux R, Pise-Masison C, Gessain A, et al: Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood. 98:3762–3769. 2001. View Article : Google Scholar
8	Bae-Jump VL, Zhou C, Boggess JF and Gehrig PA: Arsenic trioxide (As₂O₃) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells. Reprod Sci. 15:1011–1017. 2008.
9	Kang YH and Lee SJ: The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J Cell Physiol. 217:23–33. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ahn RW, Chen F, Chen H, et al: A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res. 16:3607–3617. 2010. View Article : Google Scholar : PubMed/NCBI
11	Raju GP: Arsenic: a potentially useful poison for Hedgehog-driven cancers. J Clin Invest. 121:14–16. 2011. View Article : Google Scholar : PubMed/NCBI
12	Hu XM, Liu F and Ma R: Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. Chin J Integr Med. 16:368–377. 2010. View Article : Google Scholar : PubMed/NCBI
13	Xiang Y, Wang XB, Sun SJ, et al: Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 30:440–442. 2009.(In Chinese).
14	Li JE, Wu WL, Wang ZY and Sun GL: Apoptotic effect of As₂S₂ on K562 cells and its mechanism. Acta Pharmacol Sin. 23:991–996. 2002.
15	Mao JH, Sun XY, Liu JX, et al: As₄S₄ targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 107:21683–21688. 2010.PubMed/NCBI
16	Bairey O, Vanichkin A and Shpilberg O: Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells. Int J Lab Hematol. 32(1 Pt 1): e77–e85. 2010. View Article : Google Scholar : PubMed/NCBI
17	Redondo-Muñoz J, Escobar-Díaz E, Hernández Del Cerro M, et al: Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH₂ terminal kinase activation and PTEN upregulation. Clin Cancer Res. 16:4382–4391. 2010.PubMed/NCBI
18	Yin T, Wu YL, Sun HP, et al: Combined effects of As₄S₄ and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 104:4219–4225. 2004.
19	Zhao QH, Zhang Y, Liu Y, et al: Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. Med Oncol. 27:203–212. 2010. View Article : Google Scholar : PubMed/NCBI
20	An YL, Nie F, Wang ZY and Zhang DS: Preparation and characterization of realgar nanoparticles and their inhibitory effect on rat glioma cells. Int J Nanomedicine. 6:3187–3194. 2011. View Article : Google Scholar : PubMed/NCBI
21	Cheng YX, Liu R, Wang Q, et al: Realgar-induced apoptosis of cervical cancer cell line Siha via cytochrome c release and caspase-3 and caspase-9 activation. Chin J Integr Med. 18:359–365. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ye HQ, Gan L, Yang XL and Xu HB: Membrane-associated cytotoxicity induced by realgar in promyelocytic leukemia HL-60 cells. J Ethnopharmacol. 103:366–371. 2006. View Article : Google Scholar : PubMed/NCBI
23	Wang XB, Gao HY, Hou BL, Huang J, Xi RG and Wu LJ: Nanoparticle realgar powders induce apoptosis in U937 cells through caspase MAPK and mitochondrial pathways. Arch Pharm Res. 30:653–658. 2007. View Article : Google Scholar : PubMed/NCBI
24	Xi RG, Huang J, Li D, Wang XB and Wu LJ: Roles of PI3-K/Akt pathways in nanoparticle realgar powders-induced apoptosis in U937 cells. Acta Pharmacol Sin. 29:355–363. 2008. View Article : Google Scholar : PubMed/NCBI
25	Klein U and Dalla-Favera R: New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol. 20:377–383. 2010. View Article : Google Scholar : PubMed/NCBI
26	Damle RN, Calissano C and Chiorazzi N: Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol. 23:33–45. 2010. View Article : Google Scholar : PubMed/NCBI
27	Stacchini A, Aragno M, Vallario A, et al: MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 23:127–136. 1999. View Article : Google Scholar : PubMed/NCBI
28	Buggins AG and Pepper CJ: The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res. 34:837–842. 2010. View Article : Google Scholar : PubMed/NCBI